Ruxoprubart
Based on 1 Customer Validation
Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95.541%
- CAS 番号: 2842046-67-5
- 分子量:145.982 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG1 kappa
Human
CFB
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
AAH04143.1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
-
Immobilized Complement Factor B/CFB Protein, Human (HEK293, His, HY-P7813) can bind Ruxoprubart. The EC50 for this effect is 24.9 ng/mL.
化学情報
-
CAS 番号 2842046-67-5
-
性状 Liquid
-
分子量 145.982 kDa
-
Color Colorless to light yellow
-
SMILES
[Ruxoprubart]
-
別名
NM8074
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Peixoto VP, et al. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials. Curr Med Res Opin. Published online May 16, 2024. [Content Brief]
[2]. Kavanagh D, et al. Factor B as a therapeutic target for the treatment of complement-mediated diseases. Front Immunol. 2025;16:1537974. Published 2025 Feb 14. [Content Brief]
[3]. Gentile M, et al. Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review. J Clin Med. 2025;14(3):702. Published 2025 Jan 22. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
- Ruxoprubart
- 2842046-67-5
- NM8074
- NM 8074
- NM-8074
- Complement System
- C5 convertase
- Bb subunit
- C3b deposition
- classical complement pathway
- AP C3 convertase
- alternative complement pathway
- complement Factor B
- atypical hemolytic uremic syndrome
- paroxysmal nocturnal hemoglobinuria
- red blood cell hemolysis
- Inhibitor
- inhibitor
- inhibit